Research & Education

Thoracic Oncology Highlights from ASCO 2015 and WCLC 2015

Monday, October 12, 2015 1 p.m. EDT / 11 a.m. MDT - Recording Available

The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Laurie E. Gaspar, MD, FASTRO, FACR, MBA and feature presentations by Cliff Robinson, MD and Saiama N. Waqar, MBBS, MSCI.

Laurie Gaspar Cliff Robinson Saiama Waqar 

Program Chair - Laurie E. Gaspar, MD, FASTRO, FACR, MBA

Grohne Chair in Clinical Oncology
Department of Radiation Oncology,
University of Colorado School of Medicine
Denver, Colorado USA

Cliff Robinson, MD

Associate Professor
Chief, Stereotactic Body Radiation Therapy
Department of Radiation Oncology
Washington University School of Medicine
St. Louis, MO

Saiama N. Waqar, MBBS, MSCI

Assistant Professor of Medicine
Division of Oncology
Washington University
School of Medicine
St. Louis, MO

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speaker Advisory Board for: AstraZeneca, Genentech, BMS, Lilly,Abbvie

 

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Thoracic Oncology Highlights from ASCO 2015 and WCLC 2015

Date of Activity:

 

10/12/2015

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

Moderator - Laurie E. Gaspar, MD, FASTRO, FACR, MBA- Nothing to Disclose

Speaker-Cliff Robinson, MD

Cosultand and Stock from: Radiologica

Research Grant, Speakers Bureau, Travel paid by: Varian Medical Systems, Viewray

Research Grant from: Elekta

Speaker-Saiama N. Waqar, MBBS, MSCI- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

         Yes    

If yes, please list: Supported by an unrestricted grant from Elekta

"Thoracic Oncology Highlights from ASCO 2015 and WCLC 2015"

High impact abstracts presented on the topic of lung cancer at both ASCO 2015 and WCLC 2015 will be reviewed. Dr. Waqar will focus on updates in systemic therapy, and Dr. Robinson will focus on updates in radiation therapy.
 
After attending this program participants will be able to:

  1. Discuss the role of immune checkpoint inhibitors in lung cancer
  2. Recognize the advances in molecularly targeted therapy for lung cancer
  3. Discuss the evolving role of radiation in both early stage and locally advanced lung cancer
  4. Illustrate the controversies surrounding the management of lung cancer brain metastases

Following the presentations there will be ample opportunity for the audience to submit questions and comments to the faculty via Internet chat.

DOWNLOAD RECORDING

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

CME Information:

Financial/Commercial Relationships DISCLOSURES 

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The following Financial Disclosures are from the, moderators, reviewers, and planning committee members (et.al.) their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to this presentation(s) or that have provided commercial support for this continuing medical education activity:  

SPEAKER DISCLOSURES:

Moderator - Laurie E. Gaspar, MD, FASTRO, FACR, MBA- Nothing to Disclose

Speaker-Cliff Robinson, MD

Cosultand and Stock from: Radiologica

Research Grant, Speakers Bureau, Travel paid by: Varian Medical Systems, Viewray

Research Grant from: Elekta

Speaker-Saiama N. Waqar, MBBS, MSCI- Nothing to Disclose

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

Supported by an unrestricted grant from Elekta.

GOAL & PURPOSE

High impact abstracts presented on the topic of lung cancer at both ASCO 2015 and WCLC 2015 will be reviewed. Dr. Waqar will focus on updates in systemic therapy, and Dr. Robinson will focus on updates in radiation therapy

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

LEARNING OBJECTIVES

After attending this program participants will:

  1. Discuss the role of immune checkpoint inhibitors in lung cancer
  2. Recognize the advances in molecularly targeted therapy for lung cancer
  3. Discuss the evolving role of radiation in both early stage and locally advanced lung cancer
  4. Illustrate the controversies surrounding the management of lung cancer brain metastases

 DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Thank you for your participation.

 

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Monday, October 12, 2015 at 1:00:00 PM EDT UTC-4 hours
Denver (U.S.A.) Monday, October 12, 2015 at 11:00:00 AM MDT UTC-6 hours
Los Angeles (U.S.A.) Monday, October 12, 2015 at 10:00:00 AM PDT UTC-7 hours
Paris (France) Monday, October 12, 2015 at 7:00:00 PM CEST UTC+2 hours
London (United Kingdom - England) Monday, October 12, 2015 at 6:00:00 PM BST UTC+1 hour
Amsterdam (Netherlands) Monday, October 12, 2015 at 7:00:00 PM CEST UTC+2 hours
Rome (Italy) Monday, October 12, 2015 at 7:00:00 PM CEST UTC+2 hours
Moscow (Russia) Monday, October 12, 2015 at 8:00:00 PM MSK UTC+3 hours
Corresponding UTC (GMT) Monday, October 12, 2015 at 5:00:00 PM    

How to use the Time Zone Converter

This series is partially supported by an unrestricted grant from Elekta.